PUMA BIOTECHNOLOGY, INC. - 8-K Filing
Puma Biotechnology reported Q1 2026 net product revenue of $42.0 million from NERLYNX and royalty revenue of $2.8 million, compared to $43.1 million and $2.9 million in the same period last year. The company recorded a GAAP net loss of $3.8 million ($0.07 per share) versus net income of $3.0 million ($0.06 per share) in Q1 2025, while non-GAAP adjusted net loss was $1.9 million ($0.04 per share), down from a profit of $5.0 million ($0.10 per share). Puma raised its full-year revenue guidance to $202–$206 million in product sales and expects net income of $16–$19 million for 2026, citing increa... (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $PBYI